Comparison of vildagliptin and alogliptin in patient with type 2 diabetes
Phase 2
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000005813
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4) severe renal dysfunction (sCr: more than 1.5mg/dl) 5)Patients who use of insulin 6)regnacy 7)Allergy for vildagliptin or alogliptin 8)Patients judged by the investigator to be ineligible for some other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Achievement rate of HbA1c <6.6%
- Secondary Outcome Measures
Name Time Method 1) Achievement rate of blood glucose <130mg/dl 2) Achievement rate of HbA1c <6.5% by sitagliptin treatment 3)Durability of vildagliptin or alogliptin